Dana-Farber Cancer Institute Extends Value of Clinical and Research Data With Oracle
-- Dana-Farber Cancer Institute, one of the leading cancer research andcare centers in the United States, is using Oracle(R) Healthcare TransactionBase (HTB) and Oracle Fusion Middleware components as the foundation for itsnew translational research infrastructure.
-- The new infrastructure is designed to maximize the value of clinicaland research data, and help improve disease understanding and patient care.
-- Dana-Farber, through its research, collects large amounts of patientand clinical data, as well as thousands of biological samples. It also relieson outside data sources to advance its research and understanding of complexdiseases.
-- To design new studies and address complex questions, Dana-Farberresearchers need to aggregate clinical, sample and genomic data from withinand beyond the organization's collections.
-- Dana-Farber, like many research organizations, lacked a single,integrated data infrastructure that enables aggregation and provides acomprehensive view.
-- Using Oracle Healthcare Transaction Base, Dana-Farber created anintegrated data repository that enables researchers to access clinical andsample data using a single platform and seamlessly connect it withexperimental data.
-- The new data infrastructure helps researchers investigate clinical datamore thoroughly, make complex queries and more complete data analysis, andimprove experiment design. It also enables more rapid queries, providingresearchers with answers in minutes to queries that previously required daysto process.
-- To help ensure compliance with Health Insurance Portability andAccountability Act (HIPAA) requirements, Oracle infrastructure softwareenables Dana-Farber to match clinical data and samples from specific patientsand then remove identifying information from the data before presenting it toa researcher.
-- Dana-Farber deployed Oracle Identity Management and Oracle AccessManager, components of the Oracle Fusion Middleware suite, to enableresearchers to securely access data from any location.
-- Oracle BPEL Process Manager enables Dana-Farber to manage complexclinical data transfers securely as well as replicate processes that requiremultiple deployments across the infrastructure.
-- Dana-Farber uses Oracle Fusion Middleware to build and manage webservices that facilitate integration with third-party applications foradvanced analytics and data mining across the various data sets.
-- Dana-Farber worked with Oracle Consulting to identify requirements,design and, ultimately, deploy the solution using off-the-shelfproducts -- going live within five months after completion of the solutiondesign.
-- "Oracle Healthcare Transaction Base enabled us to securely integrateour clinical, sample and genomic data -- helping us to maximize the use ofthis information in our quest to develop a better understanding of andtreatments for serious diseases," said John Quackenbush, Ph.D., Professor ofBiostatics and Computational Biology, Dana-Farber Cancer Institute. "Weleveraged Oracle's extensive offerings to create a solution that helps ourresearchers work more securely and with greater insight. And because weleveraged Oracle's existing technology, we have a system that we could rapidlyimplement, that is scalable and extensible, and one that can serve as aframework for other organizations facing similar challenges."
-- "Health sciences organizations require advanced data integrationcapabilities, combined with analytical power and process flexibility, toeffectively support emerging translational medicine initiatives," said Neil deCrescenzo, Senior Vice President and General Manager, Oracle Health SciencesGlobal Business Unit. "Oracle solutions, such as Oracle Healthcare TransactionBase, facilitate powerful enterprise-w
You May Also Like